188 related articles for article (PubMed ID: 38524142)
1. Editorial: New immunotherapy strategies and related therapeutic targets for gastrointestinal malignancies.
Ramamoorthi G
Front Immunol; 2024; 15():1389781. PubMed ID: 38524142
[No Abstract] [Full Text] [Related]
2. Immunotherapy in gastrointestinal cancer: Recent results, current studies and future perspectives.
Moehler M; Delic M; Goepfert K; Aust D; Grabsch HI; Halama N; Heinrich B; Julie C; Lordick F; Lutz MP; Mauer M; Alsina Maqueda M; Schild H; Schimanski CC; Wagner AD; Roth A; Ducreux M
Eur J Cancer; 2016 May; 59():160-170. PubMed ID: 27039171
[TBL] [Abstract][Full Text] [Related]
3. Immune Checkpoint Inhibitors in the Treatment of Gastrointestinal Malignancies: A Review of Current and Future Therapies.
Hsu A; Mendelson L; Almhanna K
R I Med J (2013); 2020 Apr; 103(3):33-37. PubMed ID: 32236159
[TBL] [Abstract][Full Text] [Related]
4. Gastrointestinal cancer stem cells as targets for innovative immunotherapy.
Chivu-Economescu M; Necula LG; Matei L; Dragu DL; Neagu AI; Alexiu I; Bleotu C; Diaconu CC
World J Gastroenterol; 2020 Apr; 26(14):1580-1593. PubMed ID: 32327907
[TBL] [Abstract][Full Text] [Related]
5. Immunotherapy in Gastrointestinal Malignancies.
Mizrahi J; Pant S
Adv Exp Med Biol; 2020; 1244():93-106. PubMed ID: 32301012
[TBL] [Abstract][Full Text] [Related]
6. Immunotherapy in gastrointestinal cancer: The current scenario and future perspectives.
Abdul-Latif M; Townsend K; Dearman C; Shiu KK; Khan K
Cancer Treat Rev; 2020 Aug; 88():102030. PubMed ID: 32505807
[TBL] [Abstract][Full Text] [Related]
7. Editorial: Gastrointestinal cancer immunotherapy: from drug resistance mechanisms to overcoming strategies.
Shi T; Wang H; Wei J; Wang J; Fan Y; Zheng C; Che X
Front Immunol; 2023; 14():1230591. PubMed ID: 37350965
[No Abstract] [Full Text] [Related]
8. [Advances in immune checkpoint inhibitors in gastrointestinal cancer].
Zhu XR; Zheng LZ
Zhonghua Zhong Liu Za Zhi; 2017 Sep; 39(9):646-649. PubMed ID: 28926891
[TBL] [Abstract][Full Text] [Related]
9. Current approaches to immunotherapy in noncolorectal gastrointestinal malignancies.
Jesus VHF; Felismino TC; Barros E Silva MJ; Souza E Silva V; Riechelmann RP
Clinics (Sao Paulo); 2018 Oct; 73(suppl 1):e510s. PubMed ID: 30365605
[TBL] [Abstract][Full Text] [Related]
10. Nanoengineered strategies to optimize dendritic cells for gastrointestinal tumor immunotherapy: from biology to translational medicine.
Bhargava A; Bunkar N; Khare NK; Mishra D; Mishra PK
Nanomedicine (Lond); 2014 Jul; 9(14):2187-202. PubMed ID: 25405796
[TBL] [Abstract][Full Text] [Related]
11. Current status of immunotherapy in gastrointestinal malignancies.
Lorenzen S; Lordick F; Loosen SH; Tacke F; Trautwein C; Roderburg C; Ettrich TJ; Perkhofer L; Reinacher-Schick A; Stein A
Z Gastroenterol; 2020 Jun; 58(6):542-555. PubMed ID: 32018315
[TBL] [Abstract][Full Text] [Related]
12. The overall potential of CD47 in cancer immunotherapy: with a focus on gastrointestinal tumors.
Tzatzarakis E; Hissa B; Reissfelder C; Schölch S
Expert Rev Anticancer Ther; 2019 Nov; 19(11):993-999. PubMed ID: 31686549
[No Abstract] [Full Text] [Related]
13. Engineered dendritic cells for gastrointestinal tumor immunotherapy: opportunities in translational research.
Bhargava A; Mishra D; Banerjee S; Mishra PK
J Drug Target; 2013 Feb; 21(2):126-36. PubMed ID: 23061479
[TBL] [Abstract][Full Text] [Related]
14. Outlook: Immunotherapy in Gastrointestinal Carcinoma - Innovative Strategies.
Moehler M; Göpfert K; Lenz HJ
Oncol Res Treat; 2018; 41(5):313-315. PubMed ID: 29705792
[TBL] [Abstract][Full Text] [Related]
15. Immunotherapy in Gastrointestinal Malignancies.
Surana R; Pant S
Adv Exp Med Biol; 2021; 1342():259-272. PubMed ID: 34972968
[TBL] [Abstract][Full Text] [Related]
16. Upper gastrointestinal malignancies in 2017: current perspectives and future approaches.
Solomon BL; Garrido-Laguna I
Future Oncol; 2018 Apr; 14(10):947-962. PubMed ID: 29542354
[TBL] [Abstract][Full Text] [Related]
17. Gut microbiota: impacts on gastrointestinal cancer immunotherapy.
Lau HCH; Sung JJ; Yu J
Gut Microbes; 2021; 13(1):1-21. PubMed ID: 33435800
[TBL] [Abstract][Full Text] [Related]
18. Overcoming resistance to anti-PD1 and anti-PD-L1 treatment in gastrointestinal malignancies.
Puccini A; Battaglin F; Iaia ML; Lenz HJ; Salem ME
J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32393474
[TBL] [Abstract][Full Text] [Related]
19. Targeted Immunotherapies in Gastrointestinal Cancer: From Molecular Mechanisms to Implications.
Wang DK; Zuo Q; He QY; Li B
Front Immunol; 2021; 12():705999. PubMed ID: 34447376
[TBL] [Abstract][Full Text] [Related]
20. Biomarkers for immune therapy in gastrointestinal cancers.
Weinberg BA; Hameed R; Marshall JL
Clin Adv Hematol Oncol; 2019 Feb; 17(2):109-119. PubMed ID: 30845114
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
